全文获取类型
收费全文 | 1129353篇 |
免费 | 77395篇 |
国内免费 | 1672篇 |
专业分类
耳鼻咽喉 | 15588篇 |
儿科学 | 35989篇 |
妇产科学 | 30099篇 |
基础医学 | 160355篇 |
口腔科学 | 30895篇 |
临床医学 | 100617篇 |
内科学 | 216120篇 |
皮肤病学 | 25141篇 |
神经病学 | 85889篇 |
特种医学 | 44673篇 |
外国民族医学 | 203篇 |
外科学 | 171758篇 |
综合类 | 22628篇 |
现状与发展 | 2篇 |
一般理论 | 362篇 |
预防医学 | 79361篇 |
眼科学 | 26175篇 |
药学 | 90104篇 |
7篇 | |
中国医学 | 2915篇 |
肿瘤学 | 69539篇 |
出版年
2021年 | 8569篇 |
2019年 | 8622篇 |
2018年 | 12372篇 |
2017年 | 9646篇 |
2016年 | 10946篇 |
2015年 | 12242篇 |
2014年 | 16835篇 |
2013年 | 24748篇 |
2012年 | 33938篇 |
2011年 | 35961篇 |
2010年 | 21057篇 |
2009年 | 19784篇 |
2008年 | 33565篇 |
2007年 | 35819篇 |
2006年 | 36307篇 |
2005年 | 34734篇 |
2004年 | 33196篇 |
2003年 | 31667篇 |
2002年 | 30620篇 |
2001年 | 60622篇 |
2000年 | 62005篇 |
1999年 | 51543篇 |
1998年 | 13127篇 |
1997年 | 11551篇 |
1996年 | 11463篇 |
1995年 | 10772篇 |
1994年 | 9777篇 |
1993年 | 9257篇 |
1992年 | 38250篇 |
1991年 | 36711篇 |
1990年 | 36105篇 |
1989年 | 34662篇 |
1988年 | 31214篇 |
1987年 | 30323篇 |
1986年 | 28541篇 |
1985年 | 26831篇 |
1984年 | 19572篇 |
1983年 | 16484篇 |
1982年 | 9315篇 |
1979年 | 17311篇 |
1978年 | 11697篇 |
1977年 | 10528篇 |
1976年 | 9084篇 |
1975年 | 10345篇 |
1974年 | 11885篇 |
1973年 | 11478篇 |
1972年 | 10932篇 |
1971年 | 10186篇 |
1970年 | 9381篇 |
1969年 | 9033篇 |
排序方式: 共有10000条查询结果,搜索用时 343 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
4.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
5.
Rajendrababu Sharmila Puthuran George Varghese Alia Laxmi Ananya Uduman Mohammed Sithiq Wijesinghe Hiruni Kaushalya 《International ophthalmology》2022,42(8):2609-2618
International Ophthalmology - To investigate the efficacy and safety of non-valved Aurolab aqueous drainage implant (AADI) surgery combined with phacoemulsification in eyes with refractory glaucoma... 相似文献
6.
7.
8.
9.
10.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献